Mechanistic and pharmacological characterization of PF-04457845: A highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 1, 2011, Pages 114-124

  Ahn, Kay ^a   Smith, Sarah E ^a   Liimatta, Marya B ^a   Beidler, David ^a   Sadagopan, Nalini ^a   Dudley, David T ^a   Young, Tim ^b   Wren, Paul ^b   Zhang, Yanhua ^a   Swaney, Steven ^a   Van Becelaere, Keri ^a   Blankman, Jacqueline L ^d   Nomura, Daniel K ^d   Bhattachar, Shobha N ^a   Stiff, Cory ^a   Nomanbhoy, Tyzoon K ^c   Weerapana, Eranthie ^d   Johnson, Douglas S ^a   Cravatt, Benjamin F ^d  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c ACTIVX BIOSCIENCES INC   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' CARBAMOYLBIPHENYL 3 YL UNDEC 10 YNYLCARBAMATE; 4 [3 [[5 (PENT 4 YN 1 YLOXY)PYRIDIN 2 YL]OXY]BENZYLIDENE] N (PYRIDAZIN 3 YL)PIPERIDINE 1 CARBOXAMIDE; ANANDAMIDE; CELECOXIB; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; JP 104; N (PYRIDIN 3 YL) 4 [3 [5 (TRIFLUOROMETHYL)PYRIDIN 2 YLOXY]BENZYL]PIPERIDINE 1 CARBOXAMIDE; N PHENYL 4 (QUINOLIN 3 YLMETHYL)PIPERIDINE 1 CARBOXAMIDE; N PYRIDAZIN 3 YL 4 [3 [[5 (TRIFLUOROMETHYL)PYRIDIN 2 YL]OXY]BENZYLIDENE]PIPERIDINE 1 CARBOXAMIDE; NAPROXEN; PF 04457845; PF 3845; PF 750; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BODY TEMPERATURE; BRAIN LEVEL; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; HYPERALGESIA; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KNEE OSTEOARTHRITIS; KNEE PAIN; LOCOMOTION; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

AMIDOHYDROLASES; ANIMALS; ENZYME INHIBITORS; HUMANS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; PAIN; PIPERIDINES; PYRIDAZINES; RATS; RATS, SPRAGUE-DAWLEY; UREA;

EID: 79959506821     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.180257     Document Type: Article

References (40)

1. References Ahn K, Johnson DS, Fitzgerald LR, Liimatta M, Arendse A, Stevenson T, Lund ET, Nugent RA, Nomanbhoy TK, Alexander JP, et al. (2007) Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 46:13019-13030. (Pubitemid 350086220)
2. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, Weerapana E, Sadagopan N, Liimatta M, Smith SE, et al. (2009) Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 16:411-420.
3. Ahn K, McKinney MK, and Cravatt BF (2008) Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 108:1687-1707. (Pubitemid 351796405)
4. Alexander JP and Cravatt BF (2005) Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem Biol 12:1179-1187. (Pubitemid 41628253)
5. Boger DL, Miyauchi H, Du W, Hardouin C, Fecik RA, Cheng H, Hwang I, Hedrick MP, Leung D, Acevedo O, et al. (2005) Discovery of a potent, selective, and efficacious class of reversible α-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J Med Chem 48:1849-1856. (Pubitemid 40396316)
6. Bove SE, Calcaterra SL, Brooker RM, Huber CM, Guzman RE, Juneau PL, Schrier DJ, and Kilgore KS (2003) Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetateinduced osteoarthritis. Osteoarthritis Cartilage 11:821-830. (Pubitemid 37407598)
7. Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ, Breitenbucher JG, Chaplan SR, and Webb M (2006) Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 148:102-113. (Pubitemid 43675605)
8. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, and Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98:9371-9376. (Pubitemid 32743923)
9. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, and Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fattyacid amides. Nature 384:83-87. (Pubitemid 26374593)
10. Cravatt BF, Prospero-Garcia O, Siuzdak G, Gilula NB, Henriksen SJ, Boger DL, and Lerner RA (1995) Chemical characterization of a family of brain lipids that induce sleep. Science 268:1506-1509.
11. Cravatt BF, Saghatelian A, Hawkins EG, Clement AB, Bracey MH, and Lichtman AH (2004) Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci USA 101:10821-10826. (Pubitemid 38955826)
12. Dixon WJ (1980) Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 20:441-462.
13. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, et al. (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 102:18620-18625. (Pubitemid 43011275)
14. Holt S, Comelli F, Costa B, and Fowler CJ (2005) Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbitaltreated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br J Pharmacol 146:467-476. (Pubitemid 41486689)
15. Huitron-Resendiz S, Sanchez-Alavez M, Wills DN, Cravatt BF, and Henriksen SJ (2004) Characterization of the sleep-wake patterns in mice lacking fatty acid amide hydrolase. Sleep 27:857-865. (Pubitemid 39095717)
16. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, and Vaughan CW (2006) Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147:281-288. (Pubitemid 43214685)
17. Johnson D, Stiff C, Lazerwith S, Kesten S, Fay L, Morris M, Beidler D, Liimatta M, Smith S, Dudley D, et al. (2011) Discovery of PF-04457845: A highly potent, orally bioavailable, and selective urea FAAH inhibitor. ACS Med Chem Lett 2:91-96.
18. Johnson DS, Ahn K, Kesten S, Lazerwith SE, Song Y, Morris M, Fay L, Gregory T, Stiff C, Dunbar JB Jr, et al. (2009) Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH). Bioorg Med Chem Lett 19:2865-2869.
19. Kathuria S, Gaetani S, Fegley D, Valiñ o F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76-81.
20. Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL, Cravatt BF, and Lichtman AH (2009) Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 330:902-910.
21. Kinsey SG, O'Neal ST, Long JZ, Cravatt BF, and Lichtman AH (2011) Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav 98:21-27.
22. Lambert DM, Vandevoorde S, Jonsson KO, and Fowler CJ (2002) The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr Med Chem 9:663-674. (Pubitemid 34296196)
23. Leung D, Hardouin C, Boger DL, and Cravatt BF (2003) Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat Biotechnol 21:687-691. (Pubitemid 36638097)
24. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, and Cravatt BF (2004) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311:441-448. (Pubitemid 39391527)
25. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ, Lichtman AH, Wiley JL, et al. (2009) Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci USA 106:20270-20275.
26. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, Ferri GL, Sibaev A, Storr M, and Lutz B (2004) The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113:1202-1209. (Pubitemid 38544105)
27. McKinney MK and Cravatt BF (2003) Evidence for distinct roles in catalysis for residues of the serine-serine-lysine catalytic triad of fatty acid amide hydrolase. J Biol Chem 278:37393-37399. (Pubitemid 37175258)
28. McKinney MK and Cravatt BF (2005) Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 74:411-432. (Pubitemid 40995513)
29. Mechoulam R (1986) The Pharmacohistory of Cannabis sativa. CRS Press, Boca Raton, FL.
30. Mileni M, Garfunkle J, DeMartino JK, Cravatt BF, Boger DL, and Stevens RC (2009) Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by α-ketoheterocycle inhibitors revealed from cocrystal structures. J Am Chem Soc 131:10497-10506.
31. Mileni M, Johnson DS, Wang Z, Everdeen DS, Liimatta M, Pabst B, Bhattacharya K, Nugent RA, Kamtekar S, Cravatt BF, et al. (2008) Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc Natl Acad Sci USA 105:12820-12824.
32. Naidu PS, Kinsey SG, Guo TL, Cravatt BF, and Lichtman AH (2010) Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. J Pharmacol Exp Ther 334:182-190.
33. Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, and Lichtman AH (2007) Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 192:61-70. (Pubitemid 46673891)
34. Patricelli MP, Giang DK, Stamp LM, and Burbaum JJ (2001) Direct visualization of serine hydrolase activities in complex proteomes using fluorescent active sitedirected probes. Proteomics 1:1067-1071. (Pubitemid 33696471)
35. Patricelli MP, Lovato MA, and Cravatt BF (1999) Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolases with distinct catalytic properties. Biochemistry 38:9804-9812.
36. Pomonis JD, Boulet JM, Gottshall SL, Phillips S, Sellers R, Bunton T, and Walker K (2005) Development and pharmacological characterization of a rat model of osteoarthritis pain. Pain 114:339-346. (Pubitemid 40385873)
37. Rodríguez de Fonseca F, Navarro M, Gómez R, Escuredo L, Nava F, Fu J, Murillo- Rodríguez E, Giuffrida A, LoVerme J, Gaetani S, et al. (2001) An anorexic lipid mediator regulated by feeding. Nature 414:209-212. (Pubitemid 33051235)
38. Russo R, Loverme J, La Rana G, Compton TR, Parrott J, Duranti A, Tontini A, Mor M, Tarzia G, Calignano A, et al. (2007) The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 322:236-242. (Pubitemid 46956375)
39. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, and Martin BR (1994) The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 270:219-227. (Pubitemid 24229631)
40. Speers AE, Adam GC, and Cravatt BF (2003) Activity-based protein profiling in vivo using a copper(i)-catalyzed azide-alkyne [3 + 2] cycloaddition. J Am Chem Soc 125:4686-4687. (Pubitemid 36505343)